

 Phase 2b: placebo/dupilumab
 Phase 2b: dupilumab/dupilumab
 QUEST: placebo/dupilumab
 QUEST: dupilumab/dupilumab

Week	Placebo (black)	10 mg (red)	20 mg (green)	40 mg (blue)
BL	-0.02	-0.02	-0.02	-0.02
024	0.20	0.25	0.35	0.35
8	0.25	0.30	0.35	0.35
12	0.25	0.30	0.35	0.35
24	0.25	0.30	0.35	0.35
48	0.25	0.35	0.38	0.35
72	0.25	0.35	0.38	0.35
84	0.25	0.35	0.38	0.35
96	0.25	0.30	0.35	0.35

Number of patients											
Phase 2b PBO/DPL	54	54	54	54	54	54	52		52	50	50
Phase 2b DPL/DPL	186	186	181	183	181	185	182	173	169	166	167
QUEST PBO/DPL	235	234	228	229	214	224	223	219	101	98	99
QUEST DPL/DPL	494	492	481	481	470	476	481	470	217	217	217

Week	Placebo (black)	Montelukast (blue)	Zileuton (green)
BL	0.0	0.0	0.0
024	0.28	0.32	0.38
8	0.30	0.35	0.40
12	0.32	0.38	0.42
24	0.28	0.35	0.40
48	0.28	0.35	0.42
72	0.28	0.35	0.45
84	0.28	0.32	0.42
96	0.25	0.30	0.38

[illegible]

Week	Placebo (green)	Low-dose (red)	High-dose (blue)
BL	0.0	0.0	0.0
024	0.48	0.38	0.32
8	0.50	0.42	0.38
12	0.52	0.45	0.40
24	0.50	0.48	0.42
48	0.52	0.48	0.42
72	0.55	0.48	0.40
84	0.55	0.48	0.40
96	0.45	0.42	0.38

Number of patients												
Phase 2b PBO/DPL	20	20	20	20	20	20	19	18	19	18	18	18
Phase 2b DPL/DPL	72	72	71	72	70	71	69	65	62	62	62	62
QUEST PBO/DPL	105	105	102	103	96	102	103	101	49	48	50	50
QUEST DPL/DPL	215	214	209	206	199	203	204	197	92	91	92	92

Week	Placebo (black)	10 mg (red)	20 mg (blue)	40 mg (green)
BL	0.0	0.0	0.0	0.0
024	0.25	0.35	0.30	0.45
08	0.28	0.38	0.32	0.48
12	0.25	0.35	0.30	0.45
24	0.25	0.40	0.35	0.48
48	0.22	0.42	0.40	0.52
72	0.23	0.45	0.42	0.48
84	0.25	0.42	0.40	0.45
96	0.28	0.40	0.38	0.42

Number of patients										
Phase 2b PBO/DPL	27	27	27	27	27	27		27	27	27
Phase 2b DPL/DPL	92	92	90	92	90	91	90	87	85	84
QUEST PBO/DPL	134	133	131	131	124	128	129	126	61	60
QUEST DPL/DPL	249	248	242	241	234	238	239	233	109	110